F-star Therapeutics, Inc. (FSTX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

6.47

-0.13

(-1.97%)

As of 10:29AM EDT. Market open.

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Hammer

View all chart patterns

Performance Outlook

Previous Close	6.60
Open	6.53
Bid	6.44 x 1000
Ask	6.46 x 1300
Day's Range	6.43 - 6.53
52 Week Range	2.07 - 8.36
Volume	58,589
Avg. Volume	358,209

Market Cap	139.653M
Beta (5Y Monthly)	N/A
PE Ratio (TTM)	N/A
EPS (TTM)	-1.71
Earnings Date	Nov 08, 2022 - Nov 14, 2022
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	13.50

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for FSTX

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

F-star Therapeutics, Inc.
Analyst Report: Merck & Co IncMerck & Co. is a worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an animal health division. MRK shares are included in the S&P 500.
Rating
Fair Value
Economic Moat
7 days agoArgus Research

All

GlobeNewswire
F-star Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights
Previously announced agreement for F-star Therapeutics to be acquired by invoX Pharma; transaction expected to close in the second half of 2022 License Agreement with Takeda to Develop and Commercialize a Novel Next-Generation Immuno-Oncology Bispecific Antibody TherapeuticFS118 Cleared the Futility Hurdle for the Initial Stage of the Head and Neck Acquired Resistance Cancer Trial Initiation of Combination Dosing with FS120 and KEYTRUDA® in Patients with Advanced Cancers under Supply Agreement w
- RESULT OF RIKSBANK CERTIFICATE SALE
  GlobeNewswire
- Monday evening First to Know forecast (08/15/2022)
  WTXL
GlobeNewswire
F-star Therapeutics Announces a License Agreement with Takeda for a Novel Next-Generation Immuno-oncology Bispecific Antibody
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., July 20, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star”), operating through its subsidiary, F-star Therapeutics Ltd., a clinical-stage biopharmaceutical company pioneering bispecifics in immunotherapy so more people with cancer can live longer and improved lives, today announced that it has entered into a license agreement with Takeda. Under the terms of the agreement, F-star will grant Takeda a worldwide, exclusive roy
Simply Wall St.
How Much Of F-star Therapeutics, Inc. (NASDAQ:FSTX) Do Institutions Own?
If you want to know who really controls F-star Therapeutics, Inc. ( NASDAQ:FSTX ), then you'll have to look at the...